보로노이

310210KOSDAQ자연과학 및 공학 연구개발업

49.2 / 100

Reference Date: 2026-06-10

Financial Score12.5 / 40

News Sentiment20.7 / 25

Momentum6.0 / 20

Disclosure10.0 / 15

AI Analysis: the high debt ratio poses financial risk, Operating Profit is on a declining trend. Plunged 36.8% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Boronoai is a biotech company specializing in the development of targeted therapies for cancers such as lung and breast cancer, leveraging its in-house research facilities and AI platforms to conduct early clinical trials and pursue a global licensing-out (License-Out) business model. The company focuses on kinase inhibitors, leveraging its expertise and accelerated development timelines to build competitive pipelines.

Number of Employees

149people

Average Salary

81.3M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 62.704.0Point

PBR

—Industry Average 3.243.5Point

ROE

-50.18Industry Average -32.093.5Point

1.6x industry avg (good)

Debt Ratio

57.37Industry Average 7.310.0Point

7.8x industry avg (risky)

Trend 2023~20251.5 / 10 points

Revenue Growth Rate

1.5 / 3

Operating Profit Growth Rate

0.0 / 3

Avg ▼32.8% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -52.7% (improving, 3yr)

Detailed News Sentiment

14 totalPositive 13Neutral 0Negative 1Average Sentiment Score 82.9

Positive
보로노이 "뇌전이 코호트로 추가 가속승인도 기대…미충족 수요 명확...
보로노이의 임상 1상 결과에서 뇌전이 코호트에서 높은 완전 반응률(ORR)과 우수한 내약성으로 인해 신약의 시장 진입 가능성이 크게 높아졌다.
Positive
세계 최대 암 학회 흔든 ‘차이나 쇼크’…K바이오는 ‘치료 사각지대.....
보로노이 등 K바이오 기업들이 ASCO에서 중국 단독 임상 결과를 발표하며 췌장암 치료 사각지대 공략에 성공, 시장 경쟁력 강화.
Positive
보로노이, 차세대 HER2 고형암 치료제 임상 1a상 중간결과 발표
보로노이의 HER2 고형암 치료제 VRN10 임상 1a 중간 결과 성공적 발표로 긍정적 시장 반응 예상.

Detailed Momentum

52-week position3.0Point

52w lower range (34%)

Current 186,500Won52-week high 363,50052-week low 91,700

1-month return0.0Point

1m -36.78% (strong drop)

Volume trend3.0Point

Volume flat

Detailed Disclosure

9 totalPositive 0Neutral 9Negative 0

Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-06-08
Neutral주식등의대량보유상황보고서(일반)2026-06-08
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-06-08
Neutral기업설명회(IR)개최2026-06-02
Neutral[기재정정]투자판단관련주요경영사항(임상시험계획변경승인) (VRN110755의 제 1/2상 임상시험)2026-05-27